RxDoctor Payments Data

Philip Oconnell, MD

Family Medicine · St. Marys, GANPI 1518930841

Payments from drug & device makers

$1,304in general payments, 2019–2025

Across 75 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$220
  • Abbott$161
  • AbbVie$145
  • Insulet Corporation$124
  • E.r. Squibb & Sons, L.L.C.$118
  • Novartis$70
  • plus $467 from 14 others

What the payments were for

  • Food & beverage$1,304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,304 in reported general payments places this provider in the 60th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$143,984
Medicare patients
397
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$109,687
EliquisApixaban70$79,443
XareltoRivaroxaban38$47,538
TrulicityDulaglutide36$46,639
JardianceEmpagliflozin36$42,353
MounjaroTirzepatide30$39,212
JanuviaSitagliptin Phosphate23$23,574
FarxigaDapagliflozin Propanediol11$16,004
Breo ElliptaFluticasone/Vilanterol28$15,193
EntrestoSacubitril/Valsartan11$11,556
Lantus SolostarInsulin Glargine,hum.Rec.Anlog85$8,737
Spiriva RespimatTiotropium Bromide13$7,019
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$6,210
Novolog FlexpenInsulin Aspart34$5,662
Omeprazole205$3,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$220$109,68778 claims
Lilly USA, LLCTrulicity, Mounjaro$14$85,85166 claims
PfizerEliquis$21$79,44370 claims
Johnson & JohnsonXarelto$60$47,53838 claims
AstraZenecaFarxiga$25$16,00411 claims
GSKBreo Ellipta$48$15,19328 claims
NovartisEntresto$70$11,55611 claims
AbbVieSynthroid$145$1,31927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in St. Marys

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →